

ORIGINAL
ARTICLEReduction in DHA transport to the brain of mice expressing human *APOE4* compared to *APOE2*

Milène Vandal,*† Wael Alata,* Cyntia Tremblay,* Christine Rioux-Perreault,‡ Norman Salem Jr,§ Frédéric Calon*† and Mélanie Plourde†‡

*Centre de recherche du centre Hospitalier de l'Université Laval (CHUL), Québec City, Québec, Canada

†Institut des Nutraceutiques et des Aliments Fonctionnels, Université Laval, Québec City, Québec, Canada

‡Centre de recherche sur le vieillissement, Université de Sherbrooke, Sherbrooke, Québec, Canada

§Nutritional Lipids, DSM Nutritional Products Inc., Columbia, South Carolina, USA

Abstract

Benefits on cognition from docosahexaenoic acid (DHA, 22 : 6 n-3) intake are absent in humans carrying apolipoprotein E ϵ 4 allele (*APOE4*), the most important genetic risk factor for Alzheimer's disease (AD). To test the hypothesis that carrying *APOE4* impairs DHA distribution, we evaluated plasma and brain fatty acid profiles and uptake of [¹⁴C]-DHA using *in situ* cerebral perfusion through the blood–brain barrier in 4- and 13-month-old male and female *APOE*-targeted replacement mice (*APOE2*, *APOE3*, and *APOE4*), fed with a DHA-depleted diet. Cortical and plasma DHA were 9% lower and 34% higher in *APOE4* compared to *APOE2* mice, respectively. Brain uptake of [¹⁴C]-DHA was 24% lower in

APOE4 versus *APOE2* mice. A significant relationship was established between DHA and apoE concentrations in the cortex of mice ($r^2 = 0.21$) and AD patients ($r^2 = 0.32$). Altogether, our results suggest that lower brain uptake of DHA in *APOE4* than in *APOE2* mice may limit the accumulation of DHA in cerebral tissues. These data provide a mechanistic explanation for the lack of benefit of DHA in *APOE4* carriers on cognitive function and the risk of AD.

Keywords: Alzheimer's disease, apolipoprotein E, blood–brain barrier, docosahexaenoic acid, long-chain omega-3 polyunsaturated fatty acids.

J. Neurochem. (2013) 10.1111/jnc.12640

Expression of the ϵ 4 allele of apolipoprotein E (*APOE*) is associated with an increased risk for late-onset familial as well as sporadic Alzheimer's disease (AD) (Corder *et al.* 1993; Saunders *et al.* 1993; Strittmatter *et al.* 1993). The *APOE* gene has three major isoforms in humans, namely, apoE2, apoE3, and apoE4. ApoE4 contains two arginine residues at position 112 and 158, instead of an arginine and a cysteine in apoE3 and a cysteine at both positions for apoE2 (Weisgraber *et al.* 1981). The frequency for *APOE4* allele is 13.6% in the general Caucasian population and reaches 36.7% in AD patients (Farrer *et al.* 1997). There is epidemiological evidence supporting lower risk of developing AD in *APOE2* carriers but higher risk in *APOE4* carriers (Corder *et al.* 1994; Hyman *et al.* 1996; Berlau *et al.* 2009; Small *et al.* 2004). Moreover, carrying two *APOE4* alleles increases the risk of developing AD by nearly 15 times, compared to *APOE3* (Farrer *et al.* 1997; Holtzman *et al.* 2012). Magnetic resonance imaging shows that *APOE4* carriage accelerates the rate of hippocampal volume loss in

non-demented older adults (Jak *et al.* 2007). Importantly, the alteration of apoE function caused by the *APOE4* allele has been consistently associated with a reduction in total brain apoE concentrations (Bales *et al.* 1997; Beffert *et al.* 1999).

ApoE protein transports cholesterol within the CNS and thus has an important role in brain lipid homeostasis (Boyles *et al.* 1989; Hauser *et al.* 2011). During aging, the brain

Received June 20, 2013; revised manuscript received December 12, 2013; accepted December 12, 2013.

Address correspondence and reprint requests to Mélanie Plourde, Département de médecine, Faculté de médecine et des sciences de la santé, Université de Sherbrooke, CSSS-IUGS, Pavillon D'Youville, 1036, rue Belvédère Sud, Sherbrooke, Québec, Canada, J1H 4C4. E-mail: melanie.plourde2@usherbrooke.ca; Frédéric Calon, Faculté de Pharmacie, Université Laval, Centre de recherche du CHUQ (bur. T-2-05), 2705 boulevard Laurier, Québec, Québec, Canada, G1V 4G2. E-mail: frederic.calon@crchul.ulaval.ca

Abbreviations used: AD, Alzheimer's disease; *APOE*, apolipoprotein E; BBB, blood–brain barrier; DHA, docosahexaenoic acid; PUFA, polyunsaturated fatty acids; TBS, tris-buffered saline.

loses approximately 20% of its weight, mainly in the form of lipids (Svennerholm *et al.* 1997). Among key brain lipids, long-chain n-3 polyunsaturated fatty acids (PUFA), in particular docosahexaenoic acid (DHA, 22 : 6 n-3), are enriched in cerebral tissues. Most mammals must obtain preformed DHA from their diet because of their limited capacity to synthesize DHA from short-chain n-3 PUFA (Plourde and Cunnane 2007). The importance of maintaining high DHA concentrations for optimal brain function has been highlighted by series of studies in animals (Calon *et al.* 2004; Hooijmans *et al.* 2009; Arsenault *et al.* 2011) and clinical trials (Yurko-Mauro *et al.* 2010). For instance, decreasing brain DHA has been shown to be deleterious on synaptic function, processing of amyloid precursor protein, and brain glucose uptake (Bowen and Clandinin 2002; Calon *et al.* 2004; Lim *et al.* 2005; Pifferi *et al.* 2005; Holguin *et al.* 2008; Arsenault *et al.* 2011), all of which have been demonstrated to be modulated by *APOE* genotype (Reiman *et al.* 2004; Wang *et al.* 2005; Reiman *et al.* 2009; Klein *et al.* 2010; Arold *et al.* 2012; Hashimoto *et al.* 2012; Koffie *et al.* 2012; Li *et al.* 2012; Sen *et al.* 2012; Youmans *et al.* 2012; Zhu *et al.* 2012). Therefore, speculating that *APOE4*-induced depletion in DHA may underlie some of its known detrimental effects in the aging brain becomes a plausible hypothesis that needs further attention.

Most of the data from epidemiological and animal studies converge to suggest that diets enriched in n-3 PUFA, such as DHA, may protect against AD (Morris *et al.* 2003; Calon *et al.* 2004; Cunnane *et al.* 2009; Arsenault *et al.* 2011; Barberger-Gateau *et al.* 2011), although other studies do not support such an association (Devore *et al.* 2009; Engelhart *et al.* 2002; Mazereeuw *et al.* 2012). However, when detected, the association between n-3 PUFA consumption and lower incidence of cognitive decline is lost in *APOE4* carriers (Huang *et al.* 2005; Samieri *et al.* 2011). Large randomized controlled trial performed in AD patients consuming 1.7–2.0 g per day of DHA found no improvement in cognition after 12–18 months (Freund-Levi *et al.* 2006; Quinn *et al.* 2010). However, after stratification of the study population by *APOE4* genotype, non-carriers of *APOE4* did improve their cognitive scores on Alzheimer Disease Assessment Scale–Cognitive and Mini–Mental State Examination after DHA treatment (Quinn *et al.* 2010). Suboptimal n-3 PUFA bioavailability in *APOE4* carriers is a possible explanation since (i) postprandial DHA β -oxidation is higher (Chouinard-Watkins *et al.* 2013), (ii) whole body half-life of DHA is 77% lower (Chouinard-Watkins *et al.* 2013), (iii) plasma DHA increase in response to fish oil supplementation (3 g/day for 6 weeks) is 165% lower in *APOE4* carriers compared to non-carriers (Plourde *et al.* 2009b), and (iv) unlike *APOE2* and *APOE3* carriers, n-3 PUFA concentrations in erythrocytes are not correlated with better cognitive scores in both young (11-year-old) and older participants (65-year-old) expressing the *APOE4* allele

(Whalley *et al.* 2008). Taken together, these results suggest that *APOE4* individuals might benefit less from dietary n-3 PUFA intake, possibly because of limited bioavailability in target tissue.

To determine whether the *APOE* genotype disrupts the accumulation of n-3 PUFA in the brain, we used human *APOE2*, 3, and 4 isoform-specific transgenic mice lacking a functional mouse apoE protein. First, we compared plasma and brain fatty acid profiles in mice in relation to expression of human *APOE2*, 3, or 4 in animals of 4 and 13 months of age. To further investigate whether *APOE* genotype lowers uptake of DHA through the blood–brain barrier (BBB) into the brain, we performed *in situ* brain perfusion of [¹⁴C]-DHA comparing *APOE2*, 3, and 4 mice at the same ages. Finally, we confirmed the association between DHA relative content and apoE concentrations using cortex samples from AD patients and control subjects.

Materials and methods

Animals

Male and female *APOE*-targeted replacement mice (*APOE2*, 3, and 4) and C57BL6 littermate mice were used for the study (Sullivan *et al.* 1997). Those mice were created by gene targeting and replacing mouse *APOE* with human *APOE2*, 3, or 4. *APOE* and C57BL6 control mice were purchased from Taconic (Hudson, NY, USA) and then reproduced at our animal facilities to complete the experimental groups. Animals were either killed at the age of 4.1 \pm 0.5 months (young mice) or at 13.4 \pm 1.2 months (middle-aged mice). Before the age of 4 months, animals were fed with a commercial chow diet (Teklad 2018; Harlan Laboratories, Indianapolis, IN, USA). From 4 to 13 months, animals were fed with a low n-3 PUFA, high n-6 PUFA diet (20.3% w/w carbohydrate, 66% w/w protein, and 3.9 kcal/g), as described previously (Bousquet *et al.* 2011) and detailed in Table S1. The final pelleted diet was produced by Research Diets Inc. (D04042202; New Brunswick, NJ, USA) using a formula precisely determined to avoid any batch to batch variations. The low n-3 PUFA, high n-6 PUFA diet was chosen to mimic the n-3 PUFA-deprived dietary environment of modern American society (Layé 2010) and to avoid potential confounding long-term effects of circulating DHA (Ouellet *et al.* 2009). The diet started at 4 months of age to avoid neurodevelopmental artifacts. At the end of the experimental time, mice were perfused in the heart after deep anesthesia with ketamine/xylozine for collecting organs and tissues for western immunoblotting and fatty acid profile determination, or were submitted to *in situ* cerebral perfusion (see below). After killing, the brain was rapidly removed and the parieto-temporal cortex was dissected, frozen, powdered, and kept at -80°C until lipid extraction and western blot. All experiments were performed in accordance with the Canadian Council on Animal Care and were approved by the Institutional Committee of the Centre Hospitalier de l'Université Laval (CHUL).

Patients and handling of brain tissue

Brain samples from AD patients were obtained from the Douglas Hospital Research Center Brain Bank (Montreal, Canada) and were

previously described (Julien *et al.* 2009). Written informed consent was obtained from all participants or their family for collecting brain samples after death. The diagnosis of AD was based on the neuropathologic examination and was classified into definite AD or probable AD according to the Consortium to Establish a Registry for AD (CERAD 1/2) diagnostic criteria; controls were rated as possible AD or no AD (CERAD 3/4) (Mirra *et al.* 1994).

Brain and plasma fatty acid profile

For mouse samples, total lipids were extracted from ~30 mg parieto-temporal cortex or 0.5 mL plasma samples by the method described by Folch *et al.* (1957). Total lipids were saponified and then transmethylated using 14% methanolic boron trifluoride. Fatty acid profiles were determined by gas chromatography equipped with a flame ionization detector (model 6890; Agilent, Palo Alto, CA, USA) and a 50-m BPX-70 fused capillary column (SGE, Melbourne, Australia; 0.25 mm inner diameter, 0.25 μ m film thickness) as previously described (Plourde *et al.* 2009a,b). For human brain samples, details on the methodology for fatty acid profile determination are reported elsewhere (Julien *et al.* 2009).

In situ cerebral perfusion

In situ cerebral perfusion technique was performed as described previously (Dagenais *et al.* 2000; Ouellet *et al.* 2009). This method allows the quantification of the transport of labeled molecules such as fatty acids through the BBB (Ouellet *et al.* 2009) and is performed by rigorously controlling perfusate composition, flow, and volume, in the absence of peripheral metabolism (Dagenais *et al.* 2000). Briefly, after being anesthetized with a mixture of ketamine and xylazine (140/8 mg/kg), the right common carotid artery was catheterized after a ligation of the external branch. Then, the thorax was opened, the heart was removed, and the perfusion started. The perfusion solution (bicarbonate buffered physiological saline, 128 mM NaCl, 24 mM NaHCO₃, 4.2 mM KCl, 2.4 mM NaH₂PO₄, 1.5 mM CaCl₂, 0.9 mM MgCl₂, and 9 mM D-glucose) was gassed with 95% O₂ and 5% CO₂ to reach a pH of 7.4 and then kept at 37°C. The perfusion flow rate was set at 1.68 mL/min for a total of 60 s after which the animal was decapitated. [¹⁴C]-DHA (0.3 μ Ci/mL, 5 μ M, Moravek Biochemicals, Brea, CA, USA) radiolabeled tracer was used to assess DHA transfer across the BBB. To quantify the vascular volume, [¹⁴C]-sucrose (0.3 μ Ci/mL) was perfused to another set of mice. After the perfusion, the brain was removed, the right hemisphere was digested in 1 mL of Solvable (Perkin-Elmer Life Sciences, Boston, MA, USA) overnight at 50°C. Nine mL of HighSafe scintillation cocktail (Perkin-Elmer Life Sciences) was added to the samples. A Wallac scintillation counter (Perkin-Elmer Life Sciences) was used to quantify ¹⁴C in the digested brain hemisphere. The volume of distribution (V_D) of [¹⁴C]-DHA was expressed in μ L/g and was calculated by dividing the concentration of [¹⁴C]-DHA in the brain (μ Ci/g) with the concentration of [¹⁴C]-DHA in the perfusate (μ Ci/ μ L). The volume of distribution (V_D) of [¹⁴C]-DHA was corrected by subtracting the vascular space (V_{vase}) also expressed in μ L/g and determined by co-perfusing [³H]-inulin (0.3 μ Ci/mL). The brain [¹⁴C]-DHA transport coefficient (Clup; mL g⁻¹s⁻¹) was calculated by dividing the corrected apparent volume of distribution of [¹⁴C]-DHA with the perfusion duration.

Western immunoblotting

Mouse parieto-temporal cortex and human parietal cortex were homogenized in eight volumes and five volumes, respectively, of Tris-buffered saline (TBS) solution containing a cocktail of proteases inhibitor (Complete™, Roche Diagnostics, Indianapolis, IN, USA) and phosphatases inhibitor [Phostop (Roche Diagnostics), sodium orthovanadate, and sodium fluoride]. Samples were sonicated and centrifuged at 100 000 g for 20 min at 4°C to generate a homogenate containing TBS-soluble proteins. Protein concentration of the resulting TBS-soluble supernatant was assessed by bicinchoninic acid protein assay kit (Pierce, Rockford, IL, USA). Twenty μ g of proteins was loaded and separated by sodium dodecyl sulfate-polyacrylamide electrophoresis gel and then electroblotted onto a polyvinylidene difluoride membrane (Immobilon, Millipore, MA, USA). Membranes were blocked in 5% milk with 0.5% bovine serum albumin for 1 h and immunoblotted with primary and then secondary antibodies followed by chemiluminescence reagents (LumiGLO Reserve Chemiluminescent Substrate Kit, KPL, Gaithersburg, MD, USA). Band intensities were determined using a KODAK Image Station 4000 MM (Molecular Imaging software version 4.0.5f7, KODAK, New Haven, CT, USA). Human apoE (1 : 20 000, Novus Biological, Littleton, CO, USA), mouse apoE (1 : 2000, Novus Biological) and actin (1 : 10 000, Applied Biological Materials, Richmond, BC, Canada) antibody were used as primary antibody.

Statistical analysis

Data are presented as the Mean \pm SEM. As no statistical difference has been found between males and females, both gender were combined in each graph to enhance the statistical power. To achieve a probability higher than 90% of not committing a Type II error (power analysis), with expected changes of cortical DHA concentrations and brain DHA uptake estimated at 20%, a standard deviation of 20%, and an α value set at 0.05, the number of mice per group was thus set at 10. For the human study, the magnitude of change in the measured endpoints was estimated at 20% according to published data (Bertrand *et al.* 1995). With an estimated standard deviation of 40% for western blot, and α set at 0.05, the number of human participants required per group was 20 to achieve 88% power. *APOE2*, *APOE3*, and *APOE4* mice were compared by performing one-way ANOVA followed by Tukey–Kramer *post hoc* test and correlations were done using Pearson's correlation. No statistical comparison was made between young and middle-aged *APOE* mice because experiments were done separately. The number of mice per group is specified in each graph. Statistical significance was set at $p < 0.05$. All statistical analyses were performed with Prism 4 (GraphPad software, San Diego, CA, USA) software.

Results

APOE4 genotype was associated with a lower cortex DHA relative content

Fatty acid profiles were first determined in samples from the parieto-temporal cortex to assess whether the *APOE4* genotype was associated with lower relative levels of brain DHA. In the young group of mice, the arachidonic acid (ARA; 20:4 n-6) percentage was 6% higher in *APOE3*

cortex than *APOE2* mice of the same age (Fig. 1a, $p < 0.05$). In separate experiments performed in 13-month-old mice, we noticed a higher proportion of n-6 docosapentaenoic acid (n-6 DPA, 22 : 5 n-6) in *APOE3* mice (Fig. 1b, +10%, $p < 0.05$) compared to *APOE2* mice. Interestingly, among PUFAs, DHA was particularly sensitive to *APOE4* genotype as DHA proportion was 9% lower in 13-month-old *APOE4* mice compared to *APOE2* mice of the same age (Fig. 1b).

APOE genotype modulates plasma fatty acid profile in young and old mice

n-6 and n-3 PUFA plasma composition was similar between groups in young mice (Fig. 2a); however, significant changes were detected in 13-month-old mice. The relative content of total n-6 PUFA was 15% higher in *APOE4* mice compared with other genotypes ($p < 0.05$), whereas total n-3 PUFA were nearly 40% higher in both *APOE3* and *APOE4* mice (Fig. 2b, $p < 0.05$) compared to *APOE2* mice. More specifically, *APOE3* and *APOE4* expression led to 64% and 77% higher percentage of ARA in plasma total lipids compared to *APOE2* mice, respectively (Fig. 2b). In addition, 13-

month-old *APOE4* mice had 34% higher plasma DHA than *APOE2* mice (Fig. 2b, $p < 0.05$).

Reduced brain DHA uptake in *APOE4* mice

The cerebrovascular volume and physical integrity of the BBB were assessed by perfusing the vascular space markers [^{14}C]-sucrose or [^3H]-inulin, which have a very poor BBB permeability under normal conditions. No difference of vascular volume was detected (Fig. 3a and b), suggesting that no major BBB leakage occurred during the experiments and ruling out the presence of a major cerebrovascular anomaly in *APOE4* mice. The Clup for [^{14}C]-DHA was 18% lower in 4-month-old ($p < 0.05$) and 24% lower in 13-month-old ($p < 0.01$) *APOE4* mice (Fig. 3a and b, $p < 0.05$ and $p < 0.01$), compared to the *APOE2* mice, indicating that the brain transport of [^{14}C]-DHA across the BBB was reduced by *APOE4* expression in mice.

Reduced cortex human apoE content in *APOE4* mice

As previously found in the same model (Riddell *et al.* 2008; Sullivan *et al.* 2011), the concentrations of human apoE was 56% and 43% lower in *APOE4* compared to *APOE2* mice at 4

Cortex




Fig. 1 Cerebral cortex fatty acid composition (%) in 4-month-old (a) and 13-month-old mice (b), according to apolipoprotein E (*APOE*) genotype. Each fatty acid is presented as % composition within total fatty acids. Cortex arachidonic acid (i), n-6 docosapentaenoic acid (ii),

n-6 polyunsaturated fatty acids (iii), and docosahexaenoic acid (iv) were analyzed by gas chromatography. Data are presented as mean \pm SEM. One-way ANOVA followed by *post hoc* Tukey–Kramer test was used to compare data. * $p < 0.05$.




Fig. 2 Plasma fatty acid profile (%) is modulated by apolipoprotein E (APOE) genotype in 4-month-old (a) and 13-month-old mice (b). Fatty acid composition is presented as % composition within total fatty acids. Plasma arachidonic acid (i), total n-6 polyunsaturated fatty acids (ii),

docosahexaenoic acid (iii), and total n-3 polyunsaturated fatty acids (iv) were analyzed by gas chromatography. Data are presented as mean \pm SEM. One-way ANOVA, *post hoc* Tukey–Kramer was used to compare data. * $p < 0.05$; *** $p < 0.0001$.




Fig. 3 Brain docosahexaenoic acid (DHA, 22:6 n-3) uptake of 4-month-old and 13-month-old apolipoprotein E (APOE)4 mice is lowered. Brain uptake of [14 C]-DHA (i) and cerebrovascular volume (ii) in 4-month-old (a) and 13-month-old (b) mice determined with *in situ*

cerebral perfusion technique. Data are presented as mean \pm SEM. One-way ANOVA, *post hoc* Tukey–Kramer was used to compare data. * $p < 0.05$.

and 13 months of age (Fig. 4a, i; $p < 0.001$ and ii) $p < 0.05$, respectively). There was a significant difference in the TBS-soluble fraction and a similar trend was found in detergent-soluble fraction (Figure S2). These results differ from data

previously published by Youmans *et al.*, showing a reduction in apoE concentration in APOE4 mice but only in detergent-soluble fractions (Youmans *et al.* 2012). In addition, we found that brain [14 C]-DHA uptake correlated with cortical apoE




(a) Cortex human APOE content**(b) Correlations between APOE content and brain DHA uptake****(c) Correlations between APOE content and brain DHA percent**

Fig. 4 Cortex human apolipoprotein E (*APOE*) content (a) correlates with docosahexaenoic acid (DHA, 22:6 n-3) passage across the blood–brain barrier (b) and with % cortex DHA change compared to C57BL6 mice (c) in 4-month-old (i) and 13-month-old (ii) *APOE2*, 3, and 4 mice. TBS-soluble *APOE* content in cerebral cortex was determined by western blot. Data are presented as mean \pm SEM. One-way ANOVA, *post hoc* Tukey–Kramer was used to compare groups. Correlations between variables were evaluated using Pearson's correlation test. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.0001$.

concentrations in young animals (Fig. 4b, i; $r^2 = 0.34$, $p < 0.01$) and with the percentage of DHA in cortical fatty acids from young and older animals (Fig. 4c, i; $r^2 = 0.21$, $p < 0.01$ and ii) $r^2 = 0.15$, $p < 0.01$, respectively).

Cortex DHA correlated with apoE concentration in AD patients

In line with previous studies, post-mortem concentrations of apoE in the parietal cortex from AD patients were 61% lower compared with control donors (Fig. 5a, $p < 0.01$) (Bertrand *et al.* 1995; Beffert *et al.* 1999). In addition, cortical concentrations of apoE were correlated with cortex DHA

composition in AD patients (Fig. 5b, $r^2 = 0.32$, $p < 0.01$) but not in control subjects (Fig. 5b, $r^2 = 0.003$, $p = 0.81$).

Discussion

This study shows that plasma and brain fatty acid profiles as well as DHA transport across the BBB are influenced by human *APOE* genotype. Expression of human *APOE4* led to a lower proportion of DHA among brain fatty acids when compared to *APOE2* expression in mice. The *in situ* demonstration of a significantly lower transfer of DHA across the BBB in *APOE4* mice suggests that impaired uptake



(a) Parietal cortex
APOE concentration

Fig. 5 Brain apolipoprotein E (*APOE*) concentrations correlate with docosahexaenoic acid (DHA, 22:6 n-3) relative content in AD patients. *APOE* concentration in TBS-soluble fraction of the parietal cortex samples was measured by western blot. Brain DHA is presented as % composition within total fatty acids. Proportion of DHA within brain fatty acids was determined by gas chromatography. Data are presented as mean \pm SEM ($n = 20$ –22 subject/group). A Welch unpaired *t*-test was used to compare groups. Correlations between variables were evaluated using Pearson's correlation test $**p < 0.01$.

(b) Correlation between cortical
APOE and % DHA

mechanisms of DHA may have led to lower brain DHA over time. Most of the significant differences highlighted by this study were found between *APOE2* and *APOE4* mice, whereas almost no difference was observed between *APOE3* and *APOE4* mice. Therefore, our results could be equally attributed to a protective effect of *APOE2* than to a deleterious effect of *APOE4*, in line with the meta-analysis of multiple epidemiological studies yielding AD risk odds ratio of 3.68 and 0.62 for *APOE4* and *APOE2*, respectively, compared to *APOE3* carriers (www.alzgene.org).

Lower brain uptake of DHA in *APOE4* compared to *APOE2* mice: possible mechanisms and consequences

One of the most striking observations reported here is the effect of *APOE* genotype on brain of uptake of [14 C]-DHA. As evidenced by *in situ* cerebral perfusion, expression of *APOE4* led to a lower brain DHA uptake compared to *APOE3* and *APOE2* genotype in 4-month-old mice, but only compared to *APOE2* mice at 13 months. Limited diffusion of DHA in the brain can obviously have important long-term consequences. However, to understand how apoE influences brain DHA transport, one must first know how blood-borne DHA normally accesses the brain. Unfortunately, mechanisms by which DHA is transported through the BBB in the brain parenchyma are subject to controversies. It has been shown experimentally that free unbound DHA readily crosses

the BBB through simple non-saturable diffusion (Ouellet *et al.* 2009). Albeit in low concentrations at equilibrium, it is expected that enough free unbound DHA is available for the brain at any time to ensure supply to the brain (Hamilton and Brunaldi 2007; Ouellet *et al.* 2009). Supporting this view, post-mortem plasma and brain DHA concentrations correlate well in animal models (Huang *et al.* 2007; Tu *et al.* 2012) and humans (Cunnane *et al.* 2012). On the other hand, other reports suggest that the exact plasma component to which DHA is bound can influence its brain uptake or that fatty acid transporters may regulate DHA transport across endothelial cell membranes (Edmond 2001; Mitchell and Hatch 2011). Data gathered after intravenous injections of radiolabeled lipids suggests that DHA transport through the BBB is enhanced after binding to certain type of lipoproteins (Lagarde *et al.* 2001; Polozova and Salem 2007), supporting a lipoprotein-mediated DHA transport to the brain. Despite the limited knowledge available about DHA transport across the BBB, several lines of thoughts can still be proposed to explain how apoE altered brain DHA uptake. First, if binding of DHA to transporters or lipoproteins is involved, then changes in apoE conformation modifying its binding properties would limit or enhance DHA transport to organs. As an example, changes in the interaction between the apoE-DHA complex and its receptors located at the BBB may therefore enhance or lower DHA transport through the BBB. One BBB

receptor for which apoE affinity is known to differ between isoforms (*APOE4* and *APOE3* > *APOE2*) is the low-density lipoprotein receptor (LDL-R) (Mahley *et al.* 2009; Weisgraber *et al.* 1982). Secondly, the lower concentration of the apoE protein in the plasma of *APOE4* mice and humans (Fitz *et al.* 2012; Yasuno *et al.* 2012; Riddell *et al.* 2008) might result in less binding sites between lipoproteins and receptors, thereby reducing brain DHA uptake. On the other hand, however, results from the present *in situ* experiments, performed with a buffer devoid of circulating lipoproteins, strongly argue for a direct long-term effect of apoE on BBB function. The fact that DHA can cross the BBB by simple diffusion does not rule out the importance of regulatory mechanisms. Indeed, we have previously shown that chronic n-3 PUFA deprivation reduces DHA uptake into the brain, arguing that BBB permeability of DHA depends on brain needs (Ouellet *et al.* 2009). Such a view is also in agreement with recent reports on major BBB dysfunction in *APOE4* mice (Bell *et al.* 2012; Hawkes *et al.* 2012). Accordingly, the decreased passage of DHA across the BBB could result from a reduction in the cerebral vascularization in *APOE4* mice (Bell *et al.* 2012).

Impaired brain DHA uptake is associated with lower brain DHA concentrations in 13-month-old *APOE4*

A change in DHA transport would be of limited consequence *per se* if not translated into altered concentrations in cerebral tissue. Replacing the coding sequence of the mouse *APOE* gene with any of the three human *APOE* coding regions had little consequence for cortex fatty acid profiles at 4 months. Only a slightly higher relative level of ARA in young *APOE3* mice was observed. This finding is consistent with a previous study reporting no difference in the relative levels of hippocampal DHA between ~ 5-month-old *APOE3* and *APOE4* mice (Kariv-Inbal *et al.* 2012). In contrast, lower DHA relative ratio in 13-month-old *APOE4* mice indicates that long-term expression of human *APOE4* has consequences on the brain membrane composition. Lower brain DHA uptake in *APOE4* mice over 13 months of life provides a simple explanation of observing lower cortex DHA content at this time point. Yet, the reason why lower brain DHA uptake in 4-month-old *APOE4* mice does not translate into lower cortex DHA content remains unclear. Perhaps, it is simply because reduced supply of DHA needs to last over several months to translate into a significant decrease in brain DHA levels. DHA turnover in the brain is estimated to last up to 33 days in mice and 2.5 years in humans (Umhau *et al.* 2009; Rapoport *et al.* 2011). However, brain DHA half-life in *APOE4* is likely to be shorter since it was recently reported that plasma DHA half-life was 31% lower than in non-carriers (Chouinard-Watkins *et al.* 2013). Therefore, it is possible that DHA is β -oxidized faster in older animals (Plourde *et al.* 2011) leading to impaired capacity to maintain brain DHA composition, and failure to compensate

the lower transport across the BBB of DHA observed in mice expressing *APOE4*. In support to this interpretation is the loss of the correlation between DHA uptake and apoE content in old mice. In any case, these data suggest that the effect of *APOE* genotype on DHA brain uptake is present early, whereas its consequence on DHA accumulation is age dependent.

Is the rise in plasma DHA in 13-month-old *APOE4* mice the result of reduced distribution in the brain?

Old *APOE4* mice had relatively higher plasma DHA, a result in line with observations in human *APOE4* carriers showing higher DHA relative content in plasma triglycerides than non-carriers (Plourde *et al.* 2009b). This result might reflect a key role of apoE protein in plasma lipid transport from the liver to target tissues, including the brain (Mahley and Rall 2000; Anil 2007; Hooijmans and Kiliaan 2008). Indeed, the main supply source of DHA for the brain is from the plasma (Diau *et al.* 2005; Umhau *et al.* 2009). On one hand, the higher plasma composition in DHA observed here in *APOE4* compared to *APOE2* mice might be explained by an enhanced DHA carrying capacity in the blood. However, this should have been associated with increased brain DHA concentrations, which was not the case. On the other hand, such plasma data may also reflect a failure of DHA transport and distribution in target tissues, including the brain. Obviously, the lower relative DHA content found in the brain favors the second explanation, which is also supported by *in situ* perfusion data confirming a lower capacity of DHA to cross the BBB in 4-month-old as well as in 13-month-old *APOE4* mice. Therefore, the combination of the data generated here suggests that a lower brain DHA uptake in 13-month-old *APOE4* mice is associated with an accumulation of DHA in the blood and ultimately lower concentrations in cerebral tissue, in comparison to *APOE2* animals.

Brain DHA composition is linked to apoE content

The data presented hitherto is significant only if representative of what is occurring in humans. As the present experimental paradigm cannot be replicated in human volunteers, we performed linear regression analyses on brain samples from AD patients. Indeed, a significant post-mortem correlation was found between DHA and apoE concentrations in the cortex of both transgenic mice and AD patients. This last observation in both species is consistent with a dose-dependent role of apoE protein content for maintaining brain DHA composition. In line with the assumption that *APOE4* allele on AD pathogenesis is deleterious and might partly be attributed to lower apoE tissue concentrations (Farrer *et al.* 1997; Beffert *et al.* 1999). The question that now has to be investigated is whether giving a high DHA diet can reverse this association and restore brain DHA in *APOE4* carriers to a level similar to non-carriers. If this hypothesis is confirmed, there is a large potential for translational research

to the clinic. Therefore, the next step would be to determine adequate DHA intake for *APOE4* carriers for preventing cognitive decline.

In summary, our results indicate that cerebral uptake and homeostasis of DHA are largely influenced by the *APOE* genotype where *APOE4* carriers displayed lower brain uptake of DHA than non-carriers. Therefore, restoring n-3 PUFA homeostasis by providing a DHA-enriched diet should be considered in future trial studying *APOE4* carriers, ideally before the first symptoms of cognitive decline (Calon 2011). In addition, given the fact that *APOE4* carrier represents 36.7% of AD patients, these results may have important nutrigenetic consequences that need to be taken into account in future DHA supplementation trials (Barberger-Gateau *et al.* 2011). Finally, as maintaining optimal brain DHA levels is essential for cognitive health, by showing that *APOE4* expression leads to reduced uptake and accumulation of DHA in the brain, our results also suggest a possible new mechanism by which *APOE4* aggravates the risk of developing AD.

Acknowledgments and Conflict of interest disclosure

This work was supported by grants from the Canadian Institutes of Health Research (CIHR) (FC – MOP 102532, MP – MOP 119454), the Alzheimer Society Canada (FC), Institut des nutraceutiques et aliments fonctionnels, and the Canada Foundation for Innovation (10307). MP is supported by a Junior 1 FRQ-S salary award and FC by a Junior 2 FRQ-S salary award. MV is supported by a CIHR Scholarship. The fatty acid analytical work was supported by the Intramural Research Program of the NIAAA, NIH. NS works for Nutritional Lipids, DSM Nutritional Products Inc.

All experiments were conducted in compliance with the ARRIVE guidelines. The authors have no conflict of interest to declare.

Supporting information

Additional supporting information may be found in the online version of this article at the publisher's web-site:

Table S1. Description of the composition of the chow and the high n-6/low n-3 PUFA diets.

Figure S1. Plasma and cortex fatty acid profiles (%) are modulated by *APOE* genotype in 4-month-old (a) and 13-month-old mice (b).

Figure S2. Cortex membrane-bound human apoE content in (A) 4-month-old and (B) 13-month-old mice.

References

Anil E. (2007) The impact of EPA and DHA on blood lipids and lipoprotein metabolism: influence of apoE genotype. *Proc. Nutr. Soc.* **66**, 60–68.

Arold S., Sullivan P., Bilousova T. *et al.* (2012) Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer's disease and apoE TR mouse cortex. *Acta Neuropathol.* **123**, 39–52.

Arsenault D., Julien C., Tremblay C. and Calon F. (2011) DHA improves cognition and prevents dysfunction of entorhinal cortex neurons in 3xTg-AD mice. *PLoS ONE* **6**, e17397.

Bales K. R., Verina T., Dodel R. C. *et al.* (1997) Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. *Nat. Genet.* **17**, 263–264.

Barberger-Gateau P., Samieri C., Féart C. and Plourde M. (2011) Dietary omega 3 polyunsaturated fatty acids and Alzheimer's disease: interaction with apolipoprotein E genotype. *Curr. Alzheimer Res.* **8**, 479–491.

Beffert U., Cohn J. S., Petit-Turcotte C., Tremblay M., Aumont N., Ramassamy C., Davignon J. and Poirier J. (1999) Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent. *Brain Res.* **843**, 87–94.

Bell R.D., Winkler E.A., Singh I. *et al.* (2012) Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. *Nature* **485**, 512–516.

Berlau D. J., Corrada M. M., Head E. and Kawas C. H. (2009) APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. *Neurology* **72**, 829–834.

Bertrand P., Poirier J., Oda T., Finch C. E. and Pasinetti G. M. (1995) Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. *Brain Res.* **33**, 174–178.

Bousquet M., Gue K., Emond V., Julien P., Kang J. X., Cicchetti F. and Calon F. (2011) Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease. *J. Lipid Res.* **52**, 263–271.

Bowen R. A. R. and Clandinin M. T. (2002) Dietary low linolenic acid compared with docosahexaenoic acid alter synaptic plasma membrane phospholipid fatty acid composition and sodium-potassium ATPase kinetics in developing rats. *J. Neurochem.* **83**, 764–774.

Boyles J. K., Zoellner C. D., Anderson L. J., Kosik L. M., Pitas R. E., Weisgraber K. H., Hui D. Y., Mahley R. W., Gebicke-Haerter P. J. and Ignatius M. J. (1989) A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. *J. Clin. Invest.* **83**, 1015–1031.

Calon F. (2011) Omega-3 polyunsaturated fatty acids in Alzheimer's disease: key questions and partial answers. *Curr. Alzheimer Res.* **8**, 470–478.

Calon F., Lim G. P., Yang F. *et al.* (2004) Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. *Neuron* **43**, 633–645.

Chouinard-Watkins R., Rioux-Perreault C., Fortier M., Lawrence P., Zhang Y., Vohl M. C., Perron P., Brenna J. T., Cunnane S. C. and Plourde M. (2013) Disturbance in uniformly ¹³C-labeled docosahexaenoic acid metabolism in elderly humans carrying apolipoprotein E epsilon 4 allele. *Br. J. Nutr.* **110**, 1751–1759.

Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L. and Pericak-Vance M. A. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* **261**, 921–923.

Corder E. H., Saunders A. M., Risch N. J., Strittmatter W. J., Schmechel D. E., Gaskell P. C., *et al.* (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. *Nat. Genet.* **7**, 180–184.


Cunnane S. C., Plourde M., Pifferi F., Bégin M., Féart C. and Barberger-Gateau P. (2009) Fish, docosahexaenoic acid and Alzheimer's disease. *Prog. Lipid Res.* **48**, 239–256.

- Cunnane S.C., Schneider J. A., Tangney C., Tremblay-Mercier J., Fortier M., Bennett D. A. and Morris M. C. (2012) Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer's disease. *J. Alzheimers Dis.* **29**, 691–697.
- Dagenais C., Rousselle C., Pollack G. M. and Scherrmann J. M. (2000) Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. *J. Cereb. Blood Flow Metab.* **20**, 381–386.
- Devore E. E., Grodstein F., van Rooij F. J. A., Hofman A., Rosner B., Stampfer M. J., *et al.* (2009) Dietary intake of fish and omega-3 fatty acids in relation to long-term dementia risk. *Am. J. Clin. Nutr.* **90**, 170–176.
- Diau G.-Y., Hsieh A. T., Sarkadi-Nagy E. A., Wijendran V., Nathanielsz P. W. and Brenna J. T. (2005) The influence of long chain polyunsaturated supplementation on docosahexaenoic acid and arachidonic acid in baboon neonate central nervous system. *BMC Med.* **3**, 11.
- Edmond J. (2001) Essential polyunsaturated fatty acids and the barrier to the brain: the components of a model for transport. *J. Mol. Neurosci.* **16**, 181–193.
- Engelhart M. J., Geerlings M. I., Ruitenberg A., Van Swieten J. C., Hofman A., Witteman J. C. M. and Breteler M. M. B. (2002) Diet and risk of dementia: Does fat matter?: The Rotterdam Study. *Neurology* **59**, 1915–1921.
- Farrer L. A., Cupples L. A., Haines J. L., Hyman B., Kukull W. A., Mayeux R., Myers R. H., Pericak-Vance M. A., Risch N. and van Duijn C. M. (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *JAMA* **278**, 1349–1356.
- Fitz N. F., Cronican A. A., Saleem M., Fauq A. H., Chapman R., Lefterov I. and Koldamova R. (2012) Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice. *J. Neurosci.* **32**, 13125–13136.
- Folch J., Lees M. and Sloane Stanley G. H. (1957) A simple method for the isolation and purification of total lipides from animal tissues. *J. Biol. Chem.* **226**, 497–509.
- Freund-Levi Y., Eriksdotter-Jönhagen M., Cederholm T., Basun H., Faxälv-Ingvar G., Garlind A., *et al.* (2006) Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: omegaAD study: a randomized double-blind trial. *Arch. Neurol.* **63**, 1402–1408.
- Hamilton J. A. and Brunaldi K. (2007) A model for fatty acid transport into the brain. *J. Mol. Neurosci.* **33**, 12–17.
- Hashimoto T., Serrano-Pozo A., Hori Y., *et al.* (2012) Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid peptide. *J. Neurosci.* **32**, 15181–15192.
- Hauser P. S., Narayanaswami V. and Ryan R. O. (2011) Apolipoprotein E: From lipid transport to neurobiology. *Prog. Lipid Res.* **50**, 62–74.
- Hawkes C. A., Sullivan P. M., Hands S., Weller R. O., Nicoll J. A. R. and Carare R. O. (2012) Disruption of arterial perivascular drainage of amyloid- β from the brains of mice expressing the human APOE ϵ 4 allele. *PLoS ONE* **7**, e41636.
- Holguin S., Martinez J., Chow C. and Wurtman R. (2008) Dietary uridine enhances the improvement in learning and memory produced by administering DHA to gerbils. *FASEB J.* **22**, 3938–3946.
- Holtzman D. M., Herz J. and Bu G. (2012) Apolipoprotein e and apolipoprotein e receptors: normal biology and roles in Alzheimer disease. *Cold Spring Harb. Perspect. Med.* **2**, a006312.
- Hooijmans C. R. and Kiliaan A. J. (2008) Fatty acids, lipid metabolism and Alzheimer pathology. *Eur. J. Pharmacol.* **585**, 176–196.
- Hooijmans C. R., Van der Zee C. E. E. M., Dederen P. J., Brouwer K. M., Reijmer Y. D., van Groen T., Broersen L. M., Lütjohann D., Heerschap A. and Kiliaan A. J. (2009) DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice. *Neurobiol. Dis.* **33**, 482–498.
- Huang T. L., Zandi P. P., Tucker K. L., Fitzpatrick A. L., Kuller L. H., Fried L. P., Burke G. L. and Carlson M. C. (2005) Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. *Neurology* **65**, 1409–1414.
- Huang M.-C., Brenna J. T., Chao A. C., Tschanz C., Diersen-Schade D. A. and Hung H.-C. (2007) Differential tissue dose responses of (n-3) and (n-6) PUFA in neonatal piglets fed docosahexaenoate and arachidonoate. *J. Nutr.* **137**, 2049–2055.
- Hyman B. T., Gomez-Isla T., Briggs M., Chung H., Nichols S., Kohout F. and Wallace R. (1996) Apolipoprotein E and cognitive change in an elderly population. *Ann. Neurol.* **40**, 55–66.
- Jak A. J., Houston W. S., Nagel B. J., Corey-Bloom J. and Bondi M. W. (2007) Differential cross-sectional and longitudinal impact of APOE genotype on hippocampal volumes in nondemented older adults. *Dement. Geriatr. Cogn. Disord.* **23**, 382–389.
- Julien C., Tremblay C., Emond V., Lebbadi M., Salem N., Bennett D. A. and Calon F. (2009) Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. *J. Neuropathol. Exp. Neurol.* **68**, 48–58.
- Kariv-Inbal Z., Yacobson S., Berkecz R., Peter M., Janaky T., Lütjohann D., Broersen L. M., Hartmann T. and Michaelson D. M. (2012) The isoform-specific pathological effects of apoE4 in vivo are prevented by a fish oil (DHA) diet and are modified by cholesterol. *J. Alzheimers Dis.* **28**, 667–683.
- Klein R. C., Mace B. E., Moore S. D. and Sullivan P. M. (2010) Progressive loss of synaptic integrity in human apolipoprotein E4 targeted replacement mice and attenuation by apolipoprotein E2. *Neuroscience* **171**, 1265–1272.
- Koffie R. M., Hashimoto T., Tai H. C. *et al.* (2012) Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid- β . *Brain* **135**, 2155–2168.
- Lagarde M., Bernoud N., Brossard N., Lemaitre-Delaunay D., Thiès F., Croset M. and Lecerf J. (2001) Lysophosphatidylcholine as a preferred carrier form of docosahexaenoic acid to the brain. *J. Mol. Neurosci.* **16**, 201–204.
- Layé S. (2010) Polyunsaturated fatty acids, neuroinflammation and well being. *Prostaglandins Leukot. Essent. Fatty Acids* **82**, 295–303.
- Li J., Kanekiyo T., Shinohara M., Zhang Y., Ladu M. J., Xu H. and Bu G. (2012) Differential regulation of amyloid- β endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms. *J. Biol. Chem.* **287**, 44593–44601.
- Lim G. P., Calon F., Morihara T., Yang F., Teter B., Ubeda O., Salem N., Frautschy S. A. and Cole G. M. (2005) A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. *J. Neurosci.* **25**, 3032–3040.
- Mahley R. W. and Rall S. C. (2000) Apolipoprotein E: far more than a lipid transport protein. *Annu. Rev. Genomics Hum. Genet.* **1**, 507–537.
- Mahley R. W., Weisgraber K. H. and Huang Y. (2009) Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. *J. Lipid Res.* **50**(Suppl), S183–S188.
- Mazereeuw G., Lanctôt K. L., Chau S. A., Swardfager W. and Herrmann N. (2012). Effects of mega-3 fatty acids on cognitive performance: a meta-analysis. *Neurobiol. Aging* **33**, 1482. e17–29.
- Mirra S. S., Gearing M., McKeel D. W., Crain B. J., Hughes J. P., van Belle G. and Heyman A. (1994) Interlaboratory comparison of neuropathology assessments in Alzheimer's disease: a study of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD). *J. Neuropathol. Exp. Neurol.* **53**, 303–315.

- Mitchell R. W. and Hatch G. M. (2011) Fatty acid transport into the brain: of fatty acid fables and lipid tails. *Prostaglandins Leukot. Essent. Fatty Acids* **85**, 293–302.
- Morris M. C., Evans D. A., Bienias J. L., Tangney C. C., Bennett D. A., Wilson R. S., Aggarwal N. and Schneider J. (2003) Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. *Arch. Neurol.* **60**, 940–946.
- Ouellet M., Emond V., Chen C. T., Julien C., Bourasset F., Oddo S., LaFerla F., Bazinet R. P. and Calon F. (2009) Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood-brain barrier: an in situ cerebral perfusion study. *Neurochem. Int.* **55**, 476–482.
- Pifferi F., Roux F., Langelier B., Alessandri J.-M., Vancassel S., Jouin M., Lavialle M. and Guesnet P. (2005) (n-3) polyunsaturated fatty acid deficiency reduces the expression of both isoforms of the brain glucose transporter GLUT1 in rats. *J. Nutr.* **135**, 2241–2246.
- Plourde M. and Cunnane S. C. (2007) Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements. *Appl. Physiol. Nutr. Metab.* **32**, 619–634.
- Plourde M., Tremblay Mercier J., Fortier M., Pifferi F. and Cunnane S. C. (2009a) Eicosapentaenoic acid decreases postprandial β -hydroxybutyrate and free fatty acid responses in healthy young and elderly. *Nutrition* **25**, 289–294.
- Plourde M., Vohl M.-C., Vandal M., Couture P., Lemieux S. and Cunnane S. C. (2009b) Plasma n-3 fatty acid response to an n-3 fatty acid supplement is modulated by apoE 4 but not by the common PPAR- α L162V polymorphism in men. *Br. J. Nutr.* **102**, 1121.
- Plourde M., Chouinard-Watkins R., Vandal M., Zhang Y., Lawrence P., Brenna J. T. and Cunnane S. C. (2011) Plasma incorporation, apparent retroconversion and β -oxidation of 13C-docosahexaenoic acid in the elderly. *Nutr. Metab. (Lond)* **8**, 5.
- Polozova A. and Salem N. (2007) Role of liver and plasma lipoproteins in selective transport of n-3 fatty acids to tissues: a comparative study of 14C-DHA and 3H-oleic acid tracers. *J. Mol. Neurosci.* **33**, 56–66.
- Quinn J. F., Raman R., Thomas R. G. *et al.* (2010) Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. *JAMA* **304**, 1903–1911.
- Rapoport S. I., Ramadan E. and Basselin M. (2011) Docosahexaenoic acid (DHA) incorporation into the brain from plasma, as an in vivo biomarker of brain DHA metabolism and neurotransmission. *Prostaglandins Other Lipid Mediat.* **96**, 109–113.
- Reiman E. M., Chen K., Alexander G. E., Caselli R. J., Bandy D., Osborne D., Saunders A. M. and Hardy J. (2004) Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. *PNAS* **101**, 284–289.
- Reiman E. M., Chen K., Liu X. *et al.* (2009) Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. *PNAS* **106**, 6820–6825.
- Riddell D. R., Zhou H., Atchison K., Warwick H. K., Atkinson P. J., Jefferson J., *et al.* (2008) Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. *J. Neurosci.* **28**, 11445–11453.
- Samieri C., Féart C., Proust-Lima C., Peuchant E., Dartigues J.-F., Amieva H. and Barberger-Gateau P. (2011) Omega-3 fatty acids and cognitive decline: modulation by ApoE ϵ 4 allele and depression. *Neurobiol. Aging* **32**, 2317.e13–2317.e22.
- Saunders A. M., Strittmatter W. J., Schmechel D., George-Hyslop P. H., Pericak-Vance M. A., Joo S. H., Rosi B. L., Gusella J. F., Crapper-MacLachlan D. R. and Alberts M. J. (1993) Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. *Neurology* **43**, 1467–1472.
- Sen A., Alkon D. L. and Nelson T. J. (2012) Apolipoprotein E3 (ApoE3) but not ApoE4 protects against synaptic loss through increased expression of protein kinase C. *J. Biol. Chem.* **287**, 15947–15958.
- Small B. J., Rosnick C. B., Fratiglioni L. and Bäckman L. (2004) Apolipoprotein E and cognitive performance: a meta-analysis. *Psychol. Aging* **19**, 592–600.
- Strittmatter W. J., Saunders A. M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G. S. and Roses A. D. (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. *PNAS* **90**, 1977–1981.
- Sullivan P. M., Mezdour H., Aratani Y., Knouff C., Najib J., Reddick R. L., Quarfordt S. H. and Maeda N. (1997) Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. *J. Biol. Chem.* **272**, 17972–17980.
- Sullivan P. M., Han B., Liu F., Mace B. E., Ervin J. F., Wu S., *et al.* (2011) Reduced levels of human apoE4 protein in an animal model of cognitive impairment. *Neurobiol. Aging* **32**, 791–801.
- Svennerholm L., Boström K. and Jungbjer B. (1997) Changes in weight and compositions of major membrane components of human brain during the span of adult human life of Swedes. *Acta Neuropathol.* **94**, 345–352.
- Tu W. C., Mühlhäusler B. S., Yelland L. N. and Gibson R. A. (2012) Correlations between blood and tissue omega-3 LCPUFA status following dietary ALA intervention in rats. *Prostaglandins Leukot. Essent. Fatty Acids* **88**, 1–8.
- Umhau J. C., Zhou W., Carson R. E. *et al.* (2009) Imaging incorporation of circulating docosahexaenoic acid into the human brain using positron emission tomography. *J. Lipid Res.* **50**, 1259–1268.
- Wang C., Wilson W. A., Moore S. D., Mace B. E., Maeda N., Schmechel D. E. and Sullivan P. M. (2005) Human apoE4-targeted replacement mice display synaptic deficits in the absence of neuropathology. *Neurobiol. Dis.* **18**, 390–398.
- Weisgraber K. H., Rall S. C. and Mahley R. W. (1981) Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. *J. Biol. Chem.* **256**, 9077–9083.
- Weisgraber K. H., Innerarity T. L. and Mahley R. W. (1982) Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. *J. Biol. Chem.* **257**, 2518–2521.
- Whalley L. J., Deary I. J., Starr J. M., Wahle K. W., Rance K. A., Bourne V. J. and Fox H. C. (2008) n-3 Fatty acid erythrocyte membrane content, APOE varepsilon4, and cognitive variation: an observational follow-up study in late adulthood. *Am. J. Clin. Nutr.* **87**, 449–454.
- Yasuno F., Tanimukai S., Sasaki M., Ikejima C., Yamashita F., Kodama C., Hidaka S., Mizukami K. and Asada T. (2012) Effect of plasma lipids, hypertension and APOE genotype on cognitive decline. *Neurobiol. Aging* **33**, 2633–2640.
- Youmans K. L., Tai L. M., Nwabuisi-Heath E. *et al.* (2012) APOE4-specific Changes in A Accumulation in a New Transgenic Mouse Model of Alzheimer Disease. *J. Biol. Chem.* **287**, 41774–41786.
- Yurko-Mauro K., Mccarthy D., Rom D., Nelson E. B., Ryan A. S., Blackwell A., Salem N., Jr, Stedman M. and MIDAS Investigators (2010) Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. *Alzheimers Dement.* **6**, 456–464.
- Zhu Y., Nwabuisi-Heath E., Dumanis S. B., Tai L. M., Yu C., Rebeck G. W. and Ladu M. J. (2012) APOE genotype alters glial activation and loss of synaptic markers in mice. *Glia* **60**, 559–569.

Graphical Abstract

The contents of this page will be used as part of the graphical abstract of html only. It will not be published as part of main article.



Using human *APOE2*, 3, and 4 isoform-specific transgenic mice, we found a lower brain uptake of docosahexaenoic acid (DHA) in *APOE4* than in *APOE2* mice that may limit the biodistribution of DHA in cerebral tissues. These data provide a mechanistic explanation for the lack of benefit of DHA in *APOE4* carriers on cognitive function and the risk of Alzheimer's disease (AD).